kxv01 tcr lentinvivo
Gene therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2025 (NCT07196579)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Proto-oncogene protein c-fosINHIBITOR
FOS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07275853 | Phase 1 | Dec 1, 2025 | Chinese Academy of Medical Sciences, TScan Therapeutics, Inc. |
| NCT07207681 | Phase 1 | Oct 15, 2025 | Jinlin University |
| NCT07196579 | Phase 1 | Oct 1, 2025 | Anhui Medical University, TScan Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2025 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Jinlin University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1